SCHEMBL25262357

SCHEMBL25262357

OCC[C@H]1C[C@@H]1c1ccccc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2C P28335 11/20 0.59
MAOB P27338 10/20 0.59
HTR2B P41595 6/20 0.59
HTR2A P28223 4/20 0.59
MAOA P21397 7/20 0.45
KDM1A O60341 5/20 0.45
CYP2C19 P33261 4/20 0.45
CYP2B6 P20813 3/20 0.45
CYP1A2 P05177 2/20 0.45
CYP2D6 P10635 2/20 0.45
CYP2C9 P11712 2/20 0.45
LMNA P02545 2/20 0.45
TAAR1 Q96RJ0 2/20 0.45
CYP3A4 P08684 1/20 0.45
HTR1A P08908 1/20 0.45
ADRA2A P08913 1/20 0.45
CYP2A6 P11509 1/20 0.45
SLC6A2 P23975 1/20 0.45
ADRA1A P35348 1/20 0.45
DRD3 P35462 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1834561 0.83 HTR2C (0.63) HTR2CMAOBHTR2BHTR2AMAOA
SCHEMBL7492289 0.83 HTR2C (0.63) HTR2CMAOBHTR2BHTR2AMAOA
SCHEMBL9043644 0.83 HTR2C (0.63) HTR2CMAOBHTR2BHTR2AMAOA
SCHEMBL16761697 0.83 HTR2C (0.63) HTR2CMAOBHTR2BHTR2AMAOA
SCHEMBL2830644 0.80 HTR2C (0.61) HTR2CMAOBHTR2BHTR2AKDM1A
SCHEMBL13113993 0.80 HTR2C (0.59) HTR2CMAOBHTR2BHTR2ACYP2C19
SCHEMBL2829240 0.80 HTR2C (0.61) HTR2CMAOBHTR2BHTR2AKDM1A
SCHEMBL23191934 0.80 HTR2C (0.66) HTR2CMAOBHTR2BHTR2AMAOA
SCHEMBL7026793 0.80 HTR2C (0.59) HTR2CHTR2BHTR2ASLC6A2SLC6A3
SCHEMBL5680153 0.79 HTR2C (0.70) HTR2CMAOBHTR2BHTR2AMAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250320234-A1 LONP1 INHIBITOR COMPOUNDS, USES AND METHODS PRETZEL THERAPEUTICS, INC. (US) 2025-10-16 US disclosed
EP-4444728-A1 LONP1 INHIBITOR COMPOUNDS, USES AND METHODS Pretzel Therapeutics, Inc. (US) 2024-10-16 EP disclosed
WO-2023107487-A1 LONP1 INHIBITOR COMPOUNDS, USES AND METHODS PRETZEL THERAPEUTICS, INC. (US) 2023-06-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250320234-A1 LONP1 INHIBITOR COMPOUNDS, USES AND METHODS LONP1, NLN, ACAT1 HTR2C 4852/4885MAOB 1669/4885HTR2B 4687/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.